Bond W S, Carvalho M, Foulks E F
J Clin Psychiatry. 1982 Jun;43(6):256-7.
Reported is a 19-year-old manic-depressive patient who developed persistent dysarthria with coexisting apraxia while on a combination of high dose haloperidol and lithium carbonate. The speech disability occurred as a solitary symptom in a patient with normal serum lithium levels and no other signs or symptoms of lithium toxicity and persisted after lithium was discontinued and the neuroleptic changed. There were several factors which favored an association between the speech disability and the drug therapy. These included improvement during a drug-free trial: the absence of a prior history of a speech problem; the patient's marked psychotic state and anxiety: and the high dosage of haloperidol.
报告了一名19岁的双相情感障碍患者，在服用高剂量氟哌啶醇和碳酸锂联合治疗期间出现持续性构音障碍并伴有失用症。言语残疾作为唯一症状出现在血清锂水平正常且无其他锂中毒体征或症状的患者中，并且在停用锂并更换抗精神病药物后仍持续存在。有几个因素支持言语残疾与药物治疗之间存在关联。这些因素包括在停药试验期间病情改善；既往无言语问题病史；患者明显的精神病状态和焦虑；以及高剂量的氟哌啶醇。
